Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Report Presents Case Studies on Clinical Trial Failures

XTALKS VITALS NEWS

FDA

The report was meant to highlight the challenges associated with drug development, and the importance of the multistage drug approval process put in place by the FDA.

Share this!

January 27, 2017 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) has released a report which presents case studies on 22 drugs in which Phase II clinical trial success did not translate to positive results in Phase III. The report was meant to highlight the challenges associated with drug development, and the importance of the multistage drug approval process put in place by the FDA.

“Roughly 9 in 10 drugs/biologics that are tested in humans are never submitted to FDA for approval,” said the authors of the FDA report. “Typically, a candidate drug is submitted to the FDA for marketing approval after phase III testing. In recent years, there has been growing interest in exploring alternatives to requiring phase III testing before product approval, such as relying on different types of data and unvalidated surrogate endpoints.”

While the agency fills an important role by ensuring that drug products on the market are safe and effective, some have criticized the agency for the length of time it takes for a new drug to be approved. Several candidates rumored to be on President Trump’s shortlist for FDA chief – including Jim O'Neill, Balaji Srinivasan and Joseph Gulfo – have expressed criticism of the FDA’s practices in the past.



Of the 22 case studies of drugs, vaccines and medical devices presented in the FDA’s report, 14 failed to meet efficacy endpoints in Phase III clinical trials. One drug – Pfizer’s cardiovascular disease drug, torcetrapib – failed due to an undesirable safety profile, while the remaining seven drugs had both unconfirmed safety and effectiveness in Phase III.

In the case of torcetrapib, Pfizer enrolled over 15,000 participants with a history of cardiovascular events and other risk factors into their Phase III clinical trial. Though the drug decreased cholesterol levels compared to the placebo, torcetrapib was also associated with a 25 percent increased risk of suffering a major adverse cardiovascular event.

After completion of Phase II trials for the drug, Pfizer executive Jeff Kindler said that torcetrapib could be “one of the most important developments in our generation.” This case study in particular highlights the importance of late-stage safety testing prior to approval.

“The 22 cases explored in this paper demonstrate that phase 2 results can inaccurately predict safety and/or effectiveness for medical products in a wide range of diseases and patient populations,” said the report. “As a result of the Phase III studies discussed in this paper, patients outside of clinical trials were not subjected to drugs that would not benefit them or to the risk of unnecessary serious toxicities, and did not suffer unnecessary financial expenditures.”


Keywords: FDA, Drug Approvals, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Food Companies are Looking for the Next Sriracha

October 19, 2017 - The Sriracha trend might be coming to an end and companies are looking for the next big hot sauce star to feature in their line-up.

Featured In: Food News


CFIA Recalling Mechanically Tenderized Steaks in Canada for E. coli

October 19, 2017 - The Canadian Food Inspection Agency posted a recall for mechanically tenderized steaks at the request of Vantage Foods Inc. on Tuesday.

Featured In: Food News


Study: Gender May Be Important When Matching Blood Transfusion Recipients to Donors

October 19, 2017 - According to a new study published in JAMA, gender and a history of pregnancy among female donors may have an impact on how well blood donors and recipients can be matched.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Brexit – Separating Fact from Fiction


Evolving Best Practices for Working with Authors of Scientific Publications – Authorship and Beyond


Human Whole-Genome Sequencing in a New Era Defined by the Illumina® HiSeq X® and NovaSeq™ Platforms


Clinical Event Adjudication: Comprehensive and Efficient Dossier Review Using a Global On-Line Solution


Copyright © 2016-2017 Honeycomb Worldwide Inc.